- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
Webcast and Conference Call today at 4:30 p.m. ET
Royalty revenue for the quarter increased to $67.2 million
Net income was $27.4 million, or $1.30 per diluted common share
Cash and marketable securities totaled $325.1 million
Phase 2a study initiated with EDP-938 against respiratory syncytial virus (RSV) infection in a human challenge study
Hepatitis B virus (HBV) candidate EDP-514 selected for clinical development in 2019
Enanta’s HBV program continues to move ahead as Enanta announces that it has selected EDP-514, a promising inhibitor of the HBV core protein, as its first development candidate in this program. A Phase 1 study of EDP-514, consisting of evaluation of single and multiple doses of drug in healthy volunteers and incorporating a Phase 1b arm in chronic HBV patients, is planned to begin in 2019.
网络直播和电话会议于今天下午4:30举行。ET
本季度的版税收入增加至6720万美元
净收入为2740万美元,或每股稀释普通股1.30美元
现金和有价证券总计3.251亿美元
在人类攻击研究中,用EDP-938针对呼吸道合胞病毒(RSV)感染开始2a期研究
乙型肝炎病毒(HBV)候选物EDP-514于2019年选择用于临床开发
Enanta的HBV计划继续推进,因为Enanta宣布已选择EDP-514,这是一种有前途的HBV核心蛋白抑制剂,是该计划的首选开发候选者。 EDP-514的一期研究计划于2019年开始,该研究包括评估健康志愿者中单剂量和多剂量药物以及将1b期手臂纳入慢性HBV患者。 |
|